Introduction {#sec1_1}
============

The Milan criteria established the long-term survival of patients with small hepatocellular carcinomas (HCC) after orthotopic liver transplantation (OLTX) and have been a standard since publication \[[@B1]\], in contrast to the variable results for tumors larger than these criteria \[[@B2], [@B3], [@B4]\]. Despite the evident success of these criteria of one lesion \<5 cm in diameter or 3 lesions, all \<3 cm in diameter, some patients still have tumor recurrence. There has been no established treatment protocol for these patients. The benefits of chemoembolization include the treatment of a tumor in a non-cirrhotic liver. But the concerns include the possibility of damage to the hepatic artery with risk of damage or loss of the transplanted liver. The current case series describes the use of full-dose chemoembolization in 6 patients with HCC tumor recurrence confined to the liver after OLTX and the long-term results.

Methods {#sec1_2}
=======

Six patients who had pathologically proven HCC and one patient with pathologically proven neuroendocrine liver tumors (without known primary) had uneventful OLTX, followed by liver-only tumor recurrences, all within 24 months of OLTX. All patients had normal serum bilirubin at the time of recurrence and CT scans of the chest, abdomen and pelvis showed tumor only in the liver. All had percutaneous biopsy proof of tumor recurrence. Each patient was treated with chemoembolization as previously described \[[@B5], [@B6]\] using cisplatin 125 mg/m^2^. All chemotherapy was administered together with Biospheres (Embospheres 100--300 µm) embolization particles. Treatments were repeated every 3--4 months until tumor stabilization or response, and thereafter only with evidence of tumor growth without metastases. Triphasic helical CAT scans (CT scans) were performed before every clinic visit, which was typically every 2--3 months. Tumor size responses were measured after CT scans and recorded according to RECIST criteria. Toxicities were evaluated using the NCI Common Toxicity Criteria v3. Patients were followed till death except one, who is alive at the time of writing.

Results {#sec1_3}
=======

Treatments and Responses to Chemoembolization {#sec2_1}
---------------------------------------------

All 6 HCC patients received single-agent cisplatin. The number of treatment cycles is shown in **table [1](#T1){ref-type="table"}**. The patient in whom there was complete tumor response (CR) received an additional 2 cycles of treatment after CR and then treatment was stopped and the patient was followed up at the clinic with CT scans. The other patients were treated till evidence of tumor progression or metastasis. All 6 patients were evaluable for tumor responses by CT scan. Table [1](#T1){ref-type="table"} shows that there was 1 complete response (CR), 2 partial responses, 1 patient with stable tumor and 2 without response whose tumors progressed on chemoembolization. Thus, 3/6 (50% of patients) had responses and 4/6 (66.6%) had disease control. This was similar to the response rates we have previously reported in the non-transplant setting \[[@B5], [@B6]\]. During the same time period, an additional 13 patients with HCC also recurred, but with metastases that were not limited to the liver and were not treated with chemoembolization.

Treatment Toxicities {#sec2_2}
--------------------

A single patient had a greater than grade 2 bilirubin toxicity, which was transient, returning to normal within 14 days of the peak. The subsequent chemoembolization cycle was administered at 50% dose reduction, without any toxicity. An additional 3 patients had grade 3 granulocyte toxicity, which normalized within 4 weeks and required no dose reduction. No adjustments to immunosuppression schedule or dosing appeared to be required as a result of the chemotherapy.

Survival and Death {#sec2_3}
------------------

All 6 patients eventually died from their tumors; 5 of them from new metastases while on therapy and 1 from progressive liver involvement by tumor. The one patient who had a CR subsequently developed lung metastases.

Discussion {#sec1_4}
==========

The number of patients with HCC who are treated with liver transplantation is rising, especially given the long-term survival for patients with small tumors without metastases \[[@B1]\] and the increased priority given to these patients on the waiting lists for cadaveric organs, especially since the general use of the model for end-stage liver disease (MELD) in organ allocation. Several factors have been shown to be associated with an increased risk of tumor recurrence, including lymph node and vascular invasion \[[@B2]\], as well as tumor size, number and grade. The incidence of tumor recurrence seems to be around 20% \[[@B7], [@B8], [@B9], [@B10]\], with significantly lower survival in patients with recurrence than in those without. Higher survival has been reported in those recurrent patients whose tumor was resected and in those in whom it could not be \[[@B7], [@B8], [@B10], [@B11]\]. However, it is unclear if that was a consequence of the resection or differences in the HCC biology. Most recurrences, however, are not resectable, either due to tumor metastases or the presence of multifocal liver recurrences. For the latter, there are few reports from the pre-Sorafenib era, before 2008 \[[@B12]\], including the present one, of systemic \[[@B13], [@B14]\] or regional chemotherapy by chemoembolization \[[@B15], [@B16]\].

Before Sorafenib, only chemoembolization had been shown to prolong survival for unresectable HCC in randomized clinical trials \[[@B17], [@B18]\] and that was the therapy used in this case series and in 2 other reports \[[@B15], [@B16]\]. There are arguments for and against chemoembolization in the post-transplant setting. The main concern is damage to the artery supplying the graft, leading to loss of the new liver. The author is unaware of any report of this calamity. The advantages are 2-fold, namely, the known tumor-shrinking effectiveness of chemoembolization and the absence of the complications of cirrhosis and accompanying portal hypertension in this setting, unlike in unresected HCC. Since the use of Sorafenib in HCC has not so far been shown to be associated with high response rates, the combination of chemoembolization plus Sorafenib in this setting of HCC recurrences in the transplanted liver in future patients would seem to be a reasonable therapy to evaluate.

###### 

Chemoembolization in the transplanted liver

                                      Patient                                          
  ----------------------------------- ------------- ------ ------ ------ ------------- --------
  Diagnosis                           HCC           HCC    HCC    HCC    HCC           HCC
  Time to recurrence, months          3             7      18     12     11            4
  Chemotherapy                                                                         
   Drug used                          DDP           DDP    DDP    DDP    DDP           DDP
   Cycles, n                          3             5      9      8      4             4
   Response                           progressive   PR     CR     PR     progressive   stable
  Cause of death                      liver         mets   mets   mets   mets          mets
  Survival after recurrence, months   13            19     50     30     18            12
  Liver toxicity                      0             0      0      0      0             \+

DDP = Diaminodichlorocisplatinum (cisplatin); mets = metastases; PR = partial response; CR = complete response.
